Compare TNXP & III Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TNXP | III |
|---|---|---|
| Founded | 2007 | 2006 |
| Country | United States | United States |
| Employees | N/A | 1500 |
| Industry | Biotechnology: Pharmaceutical Preparations | Professional Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 192.9M | 193.7M |
| IPO Year | 2008 | 2006 |
| Metric | TNXP | III |
|---|---|---|
| Price | $12.79 | $4.14 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $5.50 |
| AVG Volume (30 Days) | ★ 525.4K | 199.4K |
| Earning Date | 05-11-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 4.46% |
| EPS Growth | 91.75 | ★ 216.67 |
| EPS | N/A | ★ 0.05 |
| Revenue | $13,107,000.00 | ★ $192,745,000.00 |
| Revenue This Year | $558.11 | $3.85 |
| Revenue Next Year | $38.29 | $4.34 |
| P/E Ratio | ★ N/A | $81.20 |
| Revenue Growth | ★ 29.85 | 4.51 |
| 52 Week Low | $10.03 | $3.74 |
| 52 Week High | $69.65 | $6.45 |
| Indicator | TNXP | III |
|---|---|---|
| Relative Strength Index (RSI) | 57.23 | 50.82 |
| Support Level | $12.43 | $3.95 |
| Resistance Level | $15.19 | $4.37 |
| Average True Range (ATR) | 1.01 | 0.14 |
| MACD | 0.20 | -0.01 |
| Stochastic Oscillator | 87.20 | 75.56 |
Tonix Pharmaceuticals Holding Corp is a fully-integrated biopharmaceutical company commercializing and developing therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases. Its portfolio consists of commercial, development and discovery-stage programs, TONMYA, an approved treatment for fibromyalgia, as well as marketed acute migraine products Zembrace SymTouch and Tosymra. The company is conducting clinical trials to evaluate TONMYA for additional indications such as depressive disorder and acute stress disorder. It is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.
Information Services Group Inc is an AI-centered technology research and advisory firm providing digital transformation and technology advisory services that help organizations optimize performance, reduce costs, and accelerate innovation. The Company's expertise includes sourcing advisory, cloud and data analytics, managed governance and risk services, network and software advisory, technology strategy and operations design, change management, and market intelligence, serving both private- and public-sector clients globally. It operates in one segment, fact-based sourcing advisory services, and operates principally in the Americas, with generate maximum revenue in Europe and the Asia Pacific.